<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02145260</url>
  </required_header>
  <id_info>
    <org_study_id>2014P000629</org_study_id>
    <nct_id>NCT02145260</nct_id>
  </id_info>
  <brief_title>Trial of Dialysate Sodium in Chronic Hospitalized Hemodialysis Patients</brief_title>
  <official_title>Randomized Trial of Dialysate Sodium in Chronic Hospitalized Hemodialysis Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Brigham and Women's Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Brigham and Women's Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Intra-dialytic hypotensive (IDH) events can be defined as an abrupt decline in blood pressure&#xD;
      that cause symptoms and/or require an intervention. They are common, affecting up to one&#xD;
      third of maintenance HD sessions. Detrimental associations include: development of myocardial&#xD;
      stunning, cerebral hypo-perfusion, vascular access thrombosis and greater mortality.&#xD;
&#xD;
      Rapid solute removal by HD generates temporary osmotic gradients between the intra-vascular&#xD;
      and intra-cellular compartments, promoting trans-cellular fluid movement and resultant&#xD;
      hypotension. Manipulation of osmotic gradients, e.g. using higher dialysate sodium (DNa), may&#xD;
      ameliorate excess SBP decline during HD.&#xD;
&#xD;
      This study aims to assess the effects of higher (142 mmol/L) versus lower (138 mmol/L)&#xD;
      dialysate sodium (DNa) use in adult chronic hemodialysis patients admitted to hospital on&#xD;
      intra-dialytic blood pressure and biomarkers of cardiac ischemia.&#xD;
&#xD;
      The investigators will randomly assign subjects to higher versus lower DNa during their&#xD;
      hospital stay, up to a maximum of six HD sessions.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">July 1, 2014</start_date>
  <completion_date type="Actual">May 3, 2021</completion_date>
  <primary_completion_date type="Actual">December 31, 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Magnitude of intra-dialytic decline in systolic blood pressure</measure>
    <time_frame>Average decline in systolic blood pressure will be measured up to a maximum of six inpatient HD sessions, occurring over a two-week time period</time_frame>
    <description>Pre minus lowest SBP</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in pre-dialysis high-sensitivity troponin I</measure>
    <time_frame>The change in pre-dialysis high sensitivity troponin I concentrations will be measured between the first and second inpatient hemodialysis sessions, occuring over a period of three days</time_frame>
    <description>Cardiac injury biomarkers</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">139</enrollment>
  <condition>Intra-dialytic Hypotension</condition>
  <arm_group>
    <arm_group_label>Lower dialysate sodium</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Dialysate sodium concentration of 138 mmol/L</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Higher dialysate sodium</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Dialysate sodium concentration of 142 mmol/L</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lower dialysate sodium (138 mmol/L; using Renasol hemodialysis concentrate)</intervention_name>
    <description>A lower dialysate sodium will bes used in the active comparator arm (138 mmol/L)</description>
    <arm_group_label>Lower dialysate sodium</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Higher dialysate sodium (142 mmol/L; using Renasol hemodialysis concentrate)</intervention_name>
    <description>A higher dialysate sodium will be used in the experimental arm (142 mmol/L)</description>
    <arm_group_label>Higher dialysate sodium</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Chronic HD (&gt;90 days)&#xD;
&#xD;
          -  Age â‰¥18y&#xD;
&#xD;
          -  Informed consent&#xD;
&#xD;
          -  First admission during study period.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Use of pressors&#xD;
&#xD;
          -  Pre-dialysis serum sodium &lt;=128mmol/L or &gt; 145 mmol/L&#xD;
&#xD;
          -  Pre-dialysis SBP &gt;180 mmHg&#xD;
&#xD;
          -  Intensive care stay earlier in admission&#xD;
&#xD;
          -  Expected length of stay &lt;24 hours (e.g. admission for HD access procedure)&#xD;
&#xD;
          -  Acute coronary syndrome within seven days&#xD;
&#xD;
          -  Acute stroke&#xD;
&#xD;
          -  Institutionalized individuals&#xD;
&#xD;
          -  Pregnancy&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Finnian Mc Causland, MB, MMSc</last_name>
    <role>Principal Investigator</role>
    <affiliation>Brigham and Women's Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Brigham and Women's Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02115</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2021</verification_date>
  <study_first_submitted>May 13, 2014</study_first_submitted>
  <study_first_submitted_qc>May 21, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 22, 2014</study_first_posted>
  <last_update_submitted>May 3, 2021</last_update_submitted>
  <last_update_submitted_qc>May 3, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">May 5, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Brigham and Women's Hospital</investigator_affiliation>
    <investigator_full_name>Finnian McCausland</investigator_full_name>
    <investigator_title>Assistant Professor of Medicine, Harvard Medical School</investigator_title>
  </responsible_party>
  <keyword>Hemodialysis</keyword>
  <keyword>Hypotension</keyword>
  <keyword>Hospitalization</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypotension</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dialysis Solutions</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

